<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025466</url>
  </required_header>
  <id_info>
    <org_study_id>EXPECT</org_study_id>
    <nct_id>NCT01025466</nct_id>
  </id_info>
  <brief_title>Exelon Patch and Combination With Memantine Comparative Trial</brief_title>
  <acronym>EXPECT</acronym>
  <official_title>A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inha University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to compare the tolerability between rivastigmine patch monotherapy
      and combination therapy with memantine in patients with Alzheimer's disease (AD). The
      secondary objective is to compare the efficacy and safety between rivastigmine patch
      monotherapy and combination therapy with memantine in patients with AD. The study hypothesis
      is that the tolerability of the combination therapy with memantine is not inferior to that of
      rivastigmine patch monotherapy in AD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, the rivastigmine patch demonstrated efficacy comparable to the highest doses of
      rivastigmine capsules, with markedly improved tolerability profile. We hypothesized that
      combination of memantine and rivastigmine patch will be safe and well tolerated and result in
      more clinical benefit in patients with AD in comparison with rivastigmine patch monotherapy,
      for the mechanisms of the drugs are different.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention rate at week 16 after randomization</measure>
    <time_frame>End point (16 weeks after randomization)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at week 16 in Alzheimer's Disease Assessment Scale-Cognitive subscale</measure>
    <time_frame>16 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at week 16 in Mini-Mental State Examination</measure>
    <time_frame>16 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at week 16 in Frontal Assessment Battery</measure>
    <time_frame>16 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at week 16 in Alzheimer's Disease Cooperative Study - Activities of Daily Living</measure>
    <time_frame>16 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at week 16 in Caregiver-Administered Neuropsychiatric Inventory</measure>
    <time_frame>16 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at week 16 in Cohen Mansfield Agitation Inventory</measure>
    <time_frame>16 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at week 16 in Clinical Dementia Rating Scale-Sum of Boxes</measure>
    <time_frame>16 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>from baseline to end-point</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>rivastigmine patch monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy with memantine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine transdermal patch (Exelon patch), memantine</intervention_name>
    <description>All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.</description>
    <arm_group_label>Combination therapy with memantine</arm_group_label>
    <other_name>exelon patch, ebixa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine transdermal patch</intervention_name>
    <description>All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.</description>
    <arm_group_label>rivastigmine patch monotherapy</arm_group_label>
    <other_name>exelon patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dementia by DSM-IV and probable AD by NINCDS-ADRDA

          -  Age of 50 to 90 years

          -  Mini-Mental State Examination (MMSE) score of 10 to 20

          -  Brain MRI or CT scan consistent with a diagnosis of probable AD

          -  The caregiver must meet the patient at least once a week and be sufficiently familiar
             with the patient to provide accurate data.

          -  Ambulatory or ambulatory-aided (is, walker or cane) ability

          -  Written informed consent will be obtained from the patient (if possible) and from the
             patient's legally acceptable representative. Even if unable to provide written
             informed consent, the patient must assent verbally to participating in the study.

        Exclusion Criteria:

          -  Patients with evidence of severe or unstable physical illness, i.e., acute and severe
             asthmatic conditions, severe or unstable cardiovascular disease, active peptic ulcer
             disease, severe hepatic or renal disease, or any medical condition which would
             prohibit them from completing the study

          -  Any psychiatric or primary neurodegenerative disorder other than AD

          -  Any patients with hearing or visual problem that can disturb the efficient evaluation
             of the patients.

          -  Any patients with a history of drug addiction or alcohol addiction for the past 10
             years

          -  Patients with bradycardia (bpm less than 50) or sick sinus syndrome or conduction
             defects (sino-atrial block, second ot third degree A-V blocks

          -  Clinically significant laboratory abnormalities to affect cognitive function
             (i.e.abnormal thyroid function test, abnormal low level of vitamin B12 or folate, or
             syphilis, etc)

          -  History of allergy to topical products containing any of the constitution of the
             patches

          -  Current diagnosis of an active skin lesion

          -  Involved in other clinical trials or treated by experimental drug within 4 weeks

          -  Patients with hypersensitivity to cholinesterase inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Inha University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital</name>
      <address>
        <city>Bucheon</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donga University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changwon Fatima Hospital</name>
      <address>
        <city>Changwon</city>
        <zip>641-560</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daejun Eulji University Hopistal</name>
      <address>
        <city>Daejun</city>
        <zip>302-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Medical Center</name>
      <address>
        <city>Goyang</city>
        <zip>41-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>412-270</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University Hospital</name>
      <address>
        <city>Iksan</city>
        <zip>570-180</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha Univeristy Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryknoll Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bobath Memorial Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyughee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sungkyunkwan University, Samsung Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>150-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>431-060</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Eulji Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>May 18, 2010</last_update_submitted>
  <last_update_submitted_qc>May 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Seong Hye Choi</name_title>
    <organization>Inha University Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

